Soligenix, Inc. (NASDAQ:SNGX) – Equities researchers at B. Riley issued their FY2025 earnings estimates for shares of Soligenix in a note issued to investors on Monday, April 5th. B. Riley analyst A. D’silva anticipates that the biopharmaceutical company will post earnings of $0.51 per share for the year. B. Riley currently has a “Hold” rating and a $2.00 price target on the stock.
Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Monday, March 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.08). Soligenix had a negative net margin of 567.04% and a negative return on equity of 328.25%.
Separately, Alliance Global Partners cut their price target on Soligenix from $7.25 to $5.75 and set a “buy” rating for the company in a report on Wednesday, December 23rd.
Shares of SNGX opened at $1.57 on Tuesday. The stock has a fifty day moving average of $1.70 and a two-hundred day moving average of $1.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.30 and a current ratio of 2.30. The company has a market capitalization of $62.83 million, a PE ratio of -2.53 and a beta of 1.42. Soligenix has a fifty-two week low of $1.21 and a fifty-two week high of $2.99.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Soligenix by 22.8% during the 4th quarter. BlackRock Inc. now owns 95,520 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 17,726 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Soligenix during the 4th quarter worth $36,000. Squarepoint Ops LLC acquired a new stake in shares of Soligenix during the 3rd quarter worth $129,000. Finally, First Wilshire Securities Management Inc. increased its holdings in shares of Soligenix by 40.0% during the 4th quarter. First Wilshire Securities Management Inc. now owns 350,000 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 9.39% of the company’s stock.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer.
Featured Article: What is a Secondary Public Offering?
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.